Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study

Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials

(2019) Stefan Schreiber et al.   ANNALS OF THE RHEUMATIC DISEASES

2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

(2019) Michael M. Ward et al.   ARTHRITIS CARE & RESEARCH

Immune cells involved in the pathogenesis of ankylosing spondylitis

(2018) Alireza Rezaiemanesh et al.   BIOMEDICINE & PHARMACOTHERAPY

Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial

(2018) Kim A. Papp et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Clinical Responses and Synovial Vascularity in Obese Rheumatoid Arthritis Patients Treated with Adalimumab and Methotrexate

(2018) Gurjit S. Kaeley et al.   JOURNAL OF RHEUMATOLOGY

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

(2018) Désirée van der Heijde et al.   LANCET

Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1)

(2017) Désirée van der Heijde et al.   JOURNAL OF RHEUMATOLOGY

Axial spondyloarthritis

(2017) Joachim Sieper et al.   LANCET

Sexual Dimorphism in the Th17 Signature of Ankylosing Spondylitis

(2016) Eric Gracey et al.   Arthritis & Rheumatology

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis

(2015) Dominique Baeten et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study

(2013) R Landewé et al.   ANNALS OF THE RHEUMATIC DISEASES

Sleep disturbances are associated with increased pain, disease activity, depression, and anxiety in ankylosing spondylitis: a case-control study

(2012) Yan Li et al.   ARTHRITIS RESEARCH & THERAPY

A stratified model for health outcomes in ankylosing spondylitis

(2011) P. Machado et al.   ANNALS OF THE RHEUMATIC DISEASES

Physical Fitness in Patients With Ankylosing Spondylitis: Comparison With Population Controls

(2011) Silje Halvorsen et al.   PHYSICAL THERAPY

Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores

(2010) P. Machado et al.   ANNALS OF THE RHEUMATIC DISEASES

Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial

(2008) D van der Heijde et al.   ANNALS OF THE RHEUMATIC DISEASES

Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine

(2008) R Landewe et al.   ANNALS OF THE RHEUMATIC DISEASES

Regulation of inflammatory responses by IL-17F

(2008) Xuexian O. Yang et al.   JOURNAL OF EXPERIMENTAL MEDICINE